For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Retatrutide, originally developed by Eli Lilly, has found a loyal fan base—even though clinical trials of the drug still ...

The Dow and S&P 500 notched new records on Thursday as US stocks mostly rose, with tech stocks under more pressure after ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

A perfect storm of clinical setbacks, intensifying competition, and internal upheaval has triggered a historic sell-off in ...

Eli Lilly cuts cash prices for Zepbound weight-loss vials on LillyDirect, offering doses from $299 to $449 as demand for ...

When 1310 S. Lake Shore Drive first caught our attention last fall, it was listed for $28.35 million—and it was hard to imagine that a home with 23-karat gold-leaf gates, frescoed walls, imported ...

In this week’s edition of InnovationRx, we look at the Forbes 30 Under 30 Healthcare list, the coming barriers to getting ...

Eli Lilly has taken a significant step towards making weight loss medications more accessible by reducing the price of their ...

Eli Lilly LLY and Novo Nordisk NVO, long-standing rivals and the two dominant forces in the GLP-1 obesity market, are now locked in an intensified battle as both companies slash prices to defend and ...

The government has just negotiated a significant price reduction for the diabetes and weight-loss treatment. The stock jumped following this news, signaling that it's not as bad as it seems at first ...